Wall Street analyst estimates for TG Therapeutics, Inc. (TGTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $0.36 | ||
| 2026-08-03 | $0.05 | $0.31 | -83.6% |
| 2026-05-06 | $0.14 | $0.23 | -39.1% |
| 2026-02-26 | $0.14 | $0.35 | -60.0% |
| 2025-11-03 | $2.43 | $0.24 | +912.5% |
| 2025-08-04 | $0.17 | $0.32 | -46.9% |
| 2025-05-05 | $0.03 | $0.18 | -83.3% |
| 2025-03-03 | $0.15 | $0.08 | +87.5% |
Valuation Ratios
| P/E Ratio | 18.34 |
| Price / Book | 13.11 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $152381 | $152381 | $152000 | $152000 | $152000 | $6.7M | $2.8M | $233.7M | $329.0M | $616.3M |
| Cost of Revenue | $62960 | $82355 | $88000 | 0 | 0 | $790000 | $265000 | $14.1M | $38.5M | $100.7M |
| Gross Profit | $89421 | $70026 | $64000 | $152000 | $152000 | $5.9M | $2.5M | $219.5M | $290.5M | $515.6M |
| Research & Development | $66.5M | $96.9M | $153.8M | $154.2M | $165.9M | $222.6M | $125.4M | $76.2M | $94.3M | $160.2M |
| Selling, General & Admin | $9.9M | $16.3M | $15.2M | $15.0M | $107.8M | $128.1M | $95.5M | $122.7M | $154.3M | $232.0M |
| Operating Expenses | $79.1M | $118.9M | $174.6M | $169.2M | $273.7M | $350.7M | $220.8M | $198.9M | $248.6M | $392.2M |
| Operating Income | -$79.0M | -$118.7M | -$174.4M | -$169.1M | -$273.6M | -$344.8M | -$218.3M | $20.6M | $41.9M | $123.3M |
| EBITDA | -$78.9M | -$118.4M | -$173.4M | -$167.3M | -$272.7M | -$342.0M | -$213.1M | $26.1M | $49.9M | $134.4M |
| Interest Expense | 0 | $1.1M | $1.7M | $5.3M | $6.3M | $5.6M | $10.2M | $12.6M | $24.0M | $26.7M |
| Pre-tax Income | -$78.3M | -$118.5M | -$173.5M | -$172.9M | -$279.4M | -$348.1M | -$223.8M | $13.1M | $25.6M | $107.4M |
| Income Tax | -$716234 | -$235739 | -$918000 | 0 | 0 | 0 | 0 | $390000 | $2.2M | -$339.8M |
| Net Income | -$78.3M | -$118.5M | -$173.5M | -$172.9M | -$279.4M | -$348.1M | -$223.8M | $12.7M | $23.4M | $447.2M |
| EPS | $-1.60 | $-1.91 | $-2.30 | $-1.96 | $-2.42 | $-2.63 | $-1.46 | $0.09 | $0.16 | $3.10 |
| EPS (Diluted) | $-1.60 | $-1.91 | $-2.30 | $-1.96 | $-2.42 | $-2.63 | $-1.46 | $0.09 | $0.15 | $2.77 |
| Shares Outstanding (Diluted) | $49.0M | $62.1M | $75.5M | $88.4M | $115.3M | $132.2M | $135.4M | $148.5M | $160.3M | $161.4M |
Price
| Price | $55.85 |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACLX · ALKS · ARWR · CRSP · IMVT · KRYS · KYMR
Explore sector: Healthcare · Biotechnology
More sections of TGTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks